Annual revenue went from KRW 29.4 billion in 2022 to KRW 27.7 billion in 2023, down 5.7 percent year on year, before rising to KRW 32.1 billion in 2024, up 16.0 percent, which was the largest year of 2022 to 2025. Revenue then came to KRW 30.9 billion in 2025, down 4.0 percent.
The company attributed the 2023 revenue drop to lower overseas sales amid a global economic slowdown. Operating profit fell from KRW 3.33 billion in 2022 to KRW 1.53 billion in 2023, down 54.1 percent, as costs rose for new businesses including the CELLINstem cosmetics line.
It recovered to KRW 2.84 billion in 2024, up 85.9 percent, before turning to an operating loss of KRW 704 million in 2025. The operating margin read 11.3 percent, 5.5 percent, 8.8 percent and then -2.3 percent in 2025.
Controlling-shareholder net income rose from KRW 3.2 billion in 2022 to KRW 4.45 billion in 2023, up 39.0 percent, and to KRW 7.13 billion in 2024, up 60.0 percent, although non-operating items such as gains on valuation of convertible bond derivatives contributed to those gains.
In 2025 the controlling-shareholder result swung to a net loss of KRW 1.1 billion. The debt-to-equity ratio rose from 64.9 percent in 2022 to 92.3 percent in 2023, then fell to 49.5 percent in 2025, when total equity stood at KRW 39.9 billion and total liabilities at KRW 19.8 billion.
Operating cash flow declined from KRW 4.46 billion in 2022 to KRW 2.02 billion in 2025. Quarterly results show an operating loss of KRW 362 million in the third quarter of 2025 and KRW 1.05 billion in the fourth quarter, followed by a first-quarter 2026 operating profit of KRW 31.54 million.
The second quarter of 2026 delivered KRW 1.2 billion, up 3,714.2 percent from the prior quarter, and the third quarter returned to an operating loss of KRW 103 million, with a controlling-shareholder net loss of KRW 1.89 billion. Controlling-shareholder net income over the last four quarters totaled KRW 2.17 billion.